Otsuka (OTCMKTS:OTSKY) Shares Gap Up – Should You Buy?

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) gapped up before the market opened on Thursday . The stock had previously closed at $32.94, but opened at $36.18. Otsuka shares last traded at $36.17, with a volume of 10,395 shares traded.

Analysts Set New Price Targets

Separately, Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Otsuka Stock Performance

The stock’s 50 day moving average price is $34.44 and its two-hundred day moving average price is $32.70. The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $38.96 billion and a price-to-earnings ratio of 15.30.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.43 by $0.16. The firm had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, analysts forecast that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 EPS for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.